Refractory Cutaneous IgA Vasculitis Treated with Omega-3 Fatty Acids

Background: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). Case Report: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and p...

Full description

Saved in:
Bibliographic Details
Published inCase reports in dermatology Vol. 8; no. 3; pp. 333 - 340
Main Authors Barnadas, Maria A., Díaz Encarnación, Montserrat M.
Format Journal Article
LanguageEnglish
Published Basel, Switzerland S. Karger AG 29.11.2016
Karger Publishers
Subjects
IgA vasculitis
Omega-3 fatty acids
Single Case
IgA vasculitis
Omega-3 fatty acids
Online AccessGet full text

Cover

More Information
Summary:Background: Omega-3 fatty acids (O3FA) have been used to treat IgA nephropathy (IgAN) but not cutaneous IgA vasculitis (IgAV). Case Report: A 47-year-old female was referred for cutaneous vasculitis. She had a 24-year history of flares of palpable purpura, arthralgia associated with hematuria, and proteinuria. We diagnosed cutaneous IgAV associated with IgAN. We administered prednisone at doses ranging from 10 to 45 mg/day to control the flares. To reduce prednisone exposure, different therapeutic strategies (colchicine, diphenhydramine, hydroxyzine, azathioprine, benzathine penicillin, and mycophenolate mofetil) were applied without success. After 11 years, therapy with O3FA capsules containing 460 mg eicosapentaenoic acid and 380 mg of docosahexaenoic acid t.i.d. was introduced, allowing the prednisone to be stopped 2 years later. When the dose of O3FA was decreased to 1 capsule on alternate days, the cutaneous flares reappeared, but they were again controlled when the patient took 1 O3FA capsule daily. Conclusions: O3FA can be useful to control cutaneous IgAV.
ISSN:1662-6567
1662-6567
DOI:10.1159/000452320